1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activity
Kathleen A. McGuire(AbbVie (United States)), Philip R. Kym(AbbVie (United States)), Prasanthi Geda, Joseph Klahn(AbbVie (United States)), Jacqueline Aguado(AbbVie (United States)), Marcia N. Paddock(California State University, San Marcos), Klinge Kelly(AbbVie (United States)), Rebecca Mathew(University of Ottawa), Kyle Halliwill(AbbVie (United States)), Carey Backus(University of Michigan), Elliot P. Farney(AbbVie (United States)), Loren Lasko(AbbVie (United States)), Cara L. Hrusch(AbbVie (United States)), Keith M. Hamel(University of Chicago), Kathleen A. Yates(Broad Institute), Ryan Duggan(AbbVie (United States)), Robert T. Manguso(Broad Institute), Patricia B. Trusk(AbbVie (United States)), Jennifer Frost(AbbVie (United States)), Christina K. Baumgartner(AbbVie (United States)), Zhaoming Xiong(AbbVie (United States)), Hakimeh Ebrahimi-Nik(Broad Institute), Liang Mu(AbbVie (United States)), Marinka Bulic(AbbVie (United States))
Cited by 1
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|853
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|770
An expanded universe of cancer targets
|Cell|2021|221
Mouse models of diabetic neuropathy
|Neurobiology of Disease|2007|194